151 results on '"W. Gonsalves"'
Search Results
2. 'Real-life' data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
3. P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
4. P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
5. P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
6. Evolutionary Robotics Applied to Hexapod Locomotion: a Comparative Study of Simulation Techniques.
7. The transferability of evolved hexapod locomotion controllers from simulation to real hardware.
8. Prey, predator and super-predator model with disease in the super-predator.
9. Neuroevolution of Inverted Pendulum Control: A Comparative Study of Simulation Techniques.
10. A comparison of neural networks and physics models as motion simulators for simple robotic evolution.
11. Periodicity and limit cycle perturbation analysis of a predator-prey model with interspecific species' interference, predator additional food and dispersal.
12. The role of predator fertility and prey threshold bounds on the global and local dynamics of a predator-prey model with a prey out-flux dilution effect.
13. Integer optimisation for the selection of a Twenty20 cricket team.
14. Evolutionary Robotics Applied to Hexapod Locomotion: a Comparative Study of Simulation Techniques
15. Prey, predator and super-predator model with disease in the super-predator
16. The transferability of evolved hexapod locomotion controllers from simulation to real hardware
17. Sickle Cell Anemia
18. The role of predator fertility and prey threshold bounds on the global and local dynamics of a predator–prey model with a prey out-flux dilution effect
19. Integer optimisation for the selection of a Twenty20 cricket team
20. Nonlinear Buckling of Woven Fabrics Part II: Recovery from Buckling and Experimental Verification
21. Nonlinear Buckling of Woven Fabrics Part I: Elastic and Nonelastic Cases
22. Rotational effects of polymeric fluids on shape of filaments in melt extruded net structures
23. Racial disparities in stage II prostate cancer outcomes in the Veterans Affairs hospital system
24. Incidence of early-onset multiple myeloma among families with endometrial carcinoma
25. ChemInform Abstract: THE CHEMISTRY OF URANIUM. PART XIX. THEORETICAL INTERPRETATION OF THE MAGNETIC SUSCEPTIBILITIES OF URANIUM(IV) IONS IN CRYSTALLINE FIELDS OF D4H AND C2V SYMMETRY
26. Geomagnetic Electrokinetrograph (GEK): A Technological Advancement in Long-Term Continuous Monitoring of Fluid Flow Velocity
27. The symmetry-based equivalence between the crystal-field and angular-overlap models as applied to some planar, pyramidal and cubic symmetries
28. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment.
29. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.
30. Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
31. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
32. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.
33. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
34. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies.
35. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
36. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
37. Muscle and fat composition in patients with newly diagnosed multiple myeloma.
38. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
39. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
40. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
41. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
42. Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
43. Outcomes after biochemical or clinical progression in patients with multiple myeloma.
44. Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience.
45. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
46. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment.
47. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis.
48. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience.
49. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.
50. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.